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In Brief
Koliaki et al. show that obese individuals
without steatohepatitis (NASH) have
increased mitochondrial respiratory rates
compared to lean ones, suggesting
hepatic mitochondrial flexibility at early
stages of obesity-related insulin
resistance. This adaptation is, however,
lost in patients with NASH, who have
lower maximal respiration, despite higher
mitochondrial mass.
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The association of hepatic mitochondrial function
with insulin resistance and non-alcoholic fatty liver
(NAFL) or steatohepatitis (NASH) remains unclear.
This study applied high-resolution respirometry to
directly quantify mitochondrial respiration in liver
biopsies of obese insulin-resistant humans without
(n = 18) or with (n = 16) histologically proven NAFL
or with NASH (n = 7) compared to lean individuals
(n = 12). Despite similar mitochondrial content,
obese humans with or without NAFL had 4.3- to
5.0-fold higher maximal respiration rates in isolated
mitochondria than lean persons. NASH patients
featured higher mitochondrial mass, but 31%–40%
lower maximal respiration, which associated with
greater hepatic insulin resistance, mitochondrial un-
coupling, and leaking activity. In NASH, augmented
hepatic oxidative stress (H2O2, lipid peroxides)
and oxidative DNA damage (8-OH-deoxyguanosine)
was paralleled by reduced anti-oxidant defense
capacity and increased inflammatory response.
These data suggest adaptation of the liver (‘‘hepatic
mitochondrial flexibility’’) at early stages of obesity-
related insulin resistance, which is subsequently
lost in NASH.
INTRODUCTION
Liver is a key organ involved in energy homeostasis and patho-
genesis of type 2 diabetes mellitus (T2DM) and non-alcoholic
fatty liver disease (NAFLD). NAFLD comprises steatosis (non-
alcoholic fatty liver [NAFL]), steatohepatitis (NASH), fibrosis,
cirrhosis, and hepatocellular carcinoma. NAFLD associates
with both hepatic and whole-body insulin resistance, suggesting
common pathogenic mechanisms (Roden, 2006).CMitochondria orchestrate energy metabolism by substrate
oxidation via b-oxidation, tricarboxylic acid cycle (TCA), adeno-
sine triphosphate (ATP) synthesis through oxidative phosphory-
lation (OXPHOS), and reactive oxygen species (ROS) formation
(Murphy, 2009). In skeletal muscle, insulin resistance may
coexist with mitochondrial alterations such as lower mitochon-
drial density, OXPHOS gene expression, and ATP synthesis
(Mootha et al., 2003;Morino et al., 2005; Szendroedi et al., 2007).
Whether similar mitochondrial alterations are also present in
livers of insulin-resistant humans remains unclear. Previous
studies applied only indirect methods to assess hepatic mito-
chondria (Koliaki and Roden, 2013). While there is some evi-
dence for impaired hepatic mitochondrial function in T2DM
(Schmid et al., 2011, Szendroedi et al., 2009) and NASH
(Pe´rez-Carreras et al., 2003; Sanyal et al., 2001), Sunny et al. re-
ported increased hepatic mitochondrial function in obese hu-
mans with NAFLD using stable isotope techniques (Sunny
et al., 2011). The latter study could neither account for mitochon-
drial content nor differentiate between NAFL and NASH. No data
on simultaneous direct measurement of OXPHOS capacity and
mitochondrial density are available in livers of humans at early
stages of insulin resistance such as obesity and NAFL.
Thus, we established in humans ex vivo high-resolution respi-
rometry (HRR) to quantify hepatic mitochondrial respiration and
combined it with measures of mitochondrial content. We
analyzed intraoperative liver samples fromobesehumanswithout
NAFL (OBE NAFL), with NAFL (OBE NAFL+), with NASH (OBE
NASH), and leanhumanswithoutNAFLD (CON).Ourdatasuggest
differential regulation of hepatic mitochondrial respiration in
obese insulin-resistant humans with and without NASH.
RESULTS
Obese Humans with NASH Have Markedly Reduced
Hepatic Insulin Sensitivity
The groups did not differ in age, gender distribution, and fasting
free fatty acids (Table 1). All obese groups had higher body mass
and resting energy expenditure than CON, but body mass did
not differ among obese groups. OBE NASH presented withell Metabolism 21, 739–746, May 5, 2015 ª2015 Elsevier Inc. 739
Table 1. Participants’ Characteristics
CON OBE NAFL OBE NAFL+ OBE NASH
Age 41 ± 3 years 39 ± 3 years 41 ± 3 years 51 ± 3 years
Gender (male/female), n 5/7 3/15 2/14 3/4
Body mass index 25.5 ± 0.7 kg/m2 48.3 ± 1.9 kg/m2a 53.7 ± 2.1 kg/m2a 47.3 ± 0.7 kg/m2a
Fasting glucose 78 ± 1 mg/dl 88 ± 3 mg/dl 87 ± 3 mg/dl 127 ± 19 mg/dla,b,c
M value 7.7 ± 0.8 mg/kg/min 3.5 ± 0.3 mg/kg/mina 2.5 ± 0.3 mg/kg/mina 1.4 ± 0.9 mg/kg/mina,b
Rd 47 ± 8 mmol/kg/min 23 ± 3 mmol/kg/mina 14 ± 1 mmol/kg/mina 15 ± 4 mmol/kg/mina
EGP suppression 82% ± 3% 76% ± 4% 73% ± 7% 59% ± 18%a,b
HbA1c 5.3% ± 0.1% 5.5% ± 0.1% 5.5% ± 0.1% 6.6% ± 0.6%a,b,c
SGOT 21 ± 1 U/l 31 ± 4 U/l 32 ± 8 U/l 58 ± 13 U/la,b,c
SGPT 24 ± 2 U/l 31 ± 13 U/l 39 ± 4 U/l 59 ± 6 U/la,b,c
Fasting free fatty acids 528 ± 73 mmol/l 618 ± 51 mmol/l 623 ± 77 mmol/l 698 ± 52 mmol/l
Fasting triglycerides 99 ± 12 mg/dl 99 ± 10 mg/dl 147 ± 18 mg/dl 261 ± 76 mg/dla,b,c
Resting energy expenditure 1,548 ± 68 kcal/day 2,096 ± 124 kcal/daya 2,233 ± 167 kcal/daya 2,080 ± 100 kcal/daya
D respiratory quotient
(clamp-basal)
0.13 ± 0.01 0.11 ± 0.03 0.03 ± 0.01a,b 0.020 ± 0.003a,b
HCL 2.1% ± 1.0% 2.6% ± 0.5% 26.9% ± 3.7%a,b 70.7% ± 2.8%a,b
NAFLD score 0.6 ± 0.3 0.6 ± 0.2 2.9 ± 0.4a,b 6.9 ± 0.6a,b
Data are represented as means ± SEM. CON (n = 12) were compared to OBE humans classified into NAFL (n = 18), NAFL+ (n = 16), and NASH (n = 7)
based on liver histology (NAFL: HCL < 5.56%, NAFLD score < 3, NAFL+: HCLR 5.56%, NAFLD score < 3, NASH: NAFLD scoreR 5). EGP, endog-
enous glucose production; HbA1c, glycosylated haemoglobin; HCL, hepatocellular lipids; NAFLD, non-alcoholic fatty liver disease; Rd, rate of glucose
disposal; SGOT, aspartate aminotransferase; SGPT, alanine aminotransferase.
ap < 0.05 versus CON
bp < 0.05 versus OBE NAFL
cp < 0.05 versus OBE NAFL+higher fasting glucose and triglycerides, glycosylated hemoglo-
bin, and liver transaminases compared to other groups. Obese
groups had markedly lower whole-body insulin sensitivity
compared to CON, but only OBENASH had lower hepatic insulin
sensitivity. Both OBE NAFL+ and NASH exhibited reduced
whole-body metabolic flexibility, assessed by indirect calorim-
etry, and higher liver fat content and NAFLD score compared
to OBE NAFL and CON.
Obese Humans without, but Not with NASH, Exhibit
Upregulated Hepatic Mitochondrial Respiration
In liver tissue, maximal uncoupled respiration (state u) related to
b-oxidation and TCA cycle activity was higher in both OBE
NAFL (+85%) and OBE NAFL+ (+50%) than in CON but
lower in NASH (51% versus OBE NAFL, 40% versus OBE
NAFL+, 10% versus CON) (Figure 1A). In isolated mitochon-
dria, maximal uncoupled respiration related to TCA cycle activity
was up to 4.3- to 5.0-fold higher in OBE NAFL and NAFL+ than
in CON, whereas the respective respiration rates were 31%–
40% lower in NASH compared to both obese groups (Figure 1B).
Similar differences were observed for state 3 respiration related
to complex I (glutamate) or combined complex I and II activity
(succinate). These alterations were seen in the presence of
higher hepatic citrate synthase activity (CSA), reflecting larger
mitochondrial mass in NASH compared to all other groups (p <
0.001) (Figure 1C). Expressing respiration rates per mitochon-
drial protein content yielded similar results (Table S1). Hepatic
mitochondrial DNA content was not different among groups
(copy numbers per cell; CON: 1,822 ± 188; OBE NAFL:
1,752 ± 122; OBE NAFL+: 1,783 ± 122; OBENASH: 1,700 ± 138).740 Cell Metabolism 21, 739–746, May 5, 2015 ª2015 Elsevier Inc.To examine whether altered respiration associates with
impaired coupling of substrate oxidation to ATP production as
suggested in obesemice (Chavin et al., 1999) and NASH patients
(Serviddio et al., 2008), we exposed isolated liver mitochondria
to several substrates and oligomycin (o), an ATP synthase inhib-
itor revealing leak respiration, and assessed mitochondrial
coupling efficiency from respiratory control ratio (RCR; state
3/state o) and leaking control ratio (LCR; state o/state u). RCR
gradually declined across all groups from CON to NASH, sug-
gesting mitochondrial uncoupling in obese humans (Figure 1D).
This was aggravated in NASH patients, who exhibited markedly
higher LCR than all other groups (Figure 1E).
To further investigate possible mechanisms underlying altered
respiration in OBE groups, we measured hepatic mRNA expres-
sion of transcription factors regulating mitochondrial biogenesis
and electron transport chain (ETC) complex protein expression.
Expression of mitochondrial transcription factor A (TFAM),
PPARg-coactivator 1a (PGC1a), and nuclear respiratory factor 1
(NRF-1) was lower in both OBE NAFL+ and NASH compared to
CON (Figures 1F–1H). Of note, expression of complexes III, IV,
and V was lower in OBE NAFL+ than in CON (Figure S1). After
correction for mitochondrial content, expression of complexes I,
III, IV, andVwas loweronly inNASH than inCONandOBENAFL.
Only NASH Patients Present with Hepatic Oxidative DNA
Damage
ROS production has been implicated in NAFLD progression
(Pessayre, 2007). Indeed, all obese groups displayed elevated
hepatic lipid peroxidation, assessed from thiobarbituric reactive
substances (TBARS) (Figure 2A). Furthermore, OBE NASH
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Figure 1. Measures of Hepatic Mitochondrial Function and Content in Lean, Obese Humans with and without Non-Alcoholic Fatty Liver and
Obese with Non-Alcoholic Steatohepatitis
(A and B) O2 fluxes (mean ± SEM; 12 CON, 18 OBE NAFL, 16 OBE NAFL+, 7 OBE NASH) in (A) whole tissue and (B) isolated mitochondria upon adenosine
diphosphate (ADP), cytochrome c (cyt c), substrates (mal, malate; oct, octanoyl-carnitine; glut, glutamate; succ, succinate), and carbonyl cyanide
4-trifluoromethoxy-phenylhydrazone (FCCP) as uncoupling factor. All fluxes are normalized to citrate synthase activity (CSA).
(C) CSA as a measure of mitochondrial mass.
(D) Respiratory control ratio (RCR) defined as state 3/state o serving as marker of mitochondrial coupling.
(E) Leaking control ratio (LCR) defined as state o/state u as an index of proton leak.
(F–H) mRNA expression of regulators of mitochondrial biogenesis (F: PGC-1a, peroxisomal proliferator-activated receptor gamma coactivator 1a; G: NRF-1,
nuclear respiratory factor 1; H: TFAM, mitochondrial transcriptional factor A).
CON, lean; OBE NAFL, obese without non-alcoholic fatty liver; OBE NAFL+, obese with non-alcoholic fatty liver; OBE NASH, obese with non-alcoholic
steatohepatitis.
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Figure 2. Oxidative Stress and Anti-Oxidant
Capacity in Obese Humanswith andwithout
NASH
(A) Hepatic thiobarbituric reactive substances
(TBARS), (B) hepatic hydrogen peroxide (H2O2), (C)
hepatic catalase activity, (D) hepatic 8-OH-deox-
yguanosine (8-OH-dG), (E) hepatic p-JNK Thr183/
Tyr185 expression, and (F) hepatic CHOP
expression. Data are represented asmeans ± SEM
(n = 7–16/group), *p < 0.05.showed greater mitochondrial H2O2 release after succinate and
antimycin-A stimulation than CON, indicating augmented ROS
production (Figure 2B). Hepatic catalase activity, reflecting
anti-oxidant defense mechanisms, was unchanged in OBE
NAFL and NAFL+ but clearly impaired in NASH (Figure 1C).
Hepatic 8-OH-deoxyguanosine (8-OH-dG), a marker of oxida-
tive DNA damage, was increased only in NASH (Figure 2D).
Animal studies suggest concomitant induction of oxidative
stress and inflammatory pathways, such as the c-Jun-N-terminal
kinase (JNK)/NFkB, during development of hepatic insulin resis-
tance (Satapati et al., 2012). In line with these data, NASH
patients had elevated hepatic JNK phosphorylation at742 Cell Metabolism 21, 739–746, May 5, 2015 ª2015 Elsevier Inc.Thr183/Tyr185 (Figure 2E). The pro-
apoptotic transcription factor CHOP, a
marker of hepatic endoplasmic reticulum
(ER) stress, tended to be higher only in
NASH (p = 0.1) (Figure 2F).
NASH Patients Show Systemic
Inflammation but Not Systemic
Oxidative Stress
Circulating adipocytokines may also play
a role in the pathogenesis of NAFLD
(Cusi, 2012). Serum interleukin-1 receptor
antagonist (IL1ra) was higher in both OBE
NAFL+ and NASH compared to CON
(Figure 3A), whereas serum interleukin-6
was elevated only in NASH (Figure 3B).
Serum fibroblast growth factor 21
(FGF21) was higher in both OBE NAFL+
and NASH than in CON and OBE NAFL
(Figure 3C). High-molecular weight adi-
ponectin was lower in all obese groups
than in CON (Figure 3E). Serum TBARS,
reflecting systemic oxidative stress,
were not different between groups
(Figure 3F).
Respiration Correlates Positively
with Whole-Body Insulin
Resistance and Hepatic Steatosis
Maximal uncoupled respiration related
to TCA cycle activity in isolated mito-
chondria correlated positively with he-
patic fat content (r = 0.476, p = 0.025)
and plasma free fatty acids (r = 0.440,
p = 0.028) and negatively with whole-body insulin sensitivity (r = 0.641, p = 0.001). Maximal un-
coupled respiration in liver tissue correlated positively with
fasting plasma glucose (r = 0.655, p < 0.001) and serum tri-
glycerides (r = 0.390, p = 0.015). Across all groups, hepatic
CSA correlated positively with NAFLD score (r = 0.593, p =
0.001), consistent with higher CSA in NASH. Whole-body in-
sulin sensitivity correlated positively with serum adiponectin
(r = 0.538, p = 0.001) and negatively with IL-6 (r = 0.468,
p = 0.006) and hepatic lipid peroxidation (r = 0.426, p =
0.019). Hepatic insulin resistance correlated positively with
serum IL-6 (r = 0.491, p = 0.005) and FGF21 (r = 0.585, p =
0.001).
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Figure 3. Circulating Markers of Inflamma-
tion and Oxidative Stress in Obese Humans
with and without NASH
Serum concentrations of (A) interleukin-1 receptor
antagonist (IL1ra), (B) interleukin-6 (IL-6), (C)
fibroblast growth factor 21 (FGF21), (D) fetuin-A,
(E) high molecular weight (HMW) adiponectin, and
(F) thiobarbituric reactive substances (TBARS).
Data are represented as means ± SEM (n = 7–17/
group), *p < 0.05.DISCUSSION
This study reports direct evidence for a compensatory upregula-
tion of hepatic mitochondrial respiration in obese insulin-resis-
tant humans with and without fatty liver. This adaptation is abol-
ished in obese humans with NASH, who also exhibit greater
hepatic insulin resistance, leaking mitochondria, hepatic oxida-Cell Metabolism 21, 739tive stress, and systemic inflammation.
These data suggest the operation of a
mechanism of ‘‘hepatic metabolic flexi-
bility,’’ by which liver mitochondria adapt
to altered bioenergetic demands preced-
ing advanced NAFLD. Of note, all obese
groups had a comparable degree of
obesity so that the observed effects are
not determined by whole-body obesity
but rather by the degree of hepatic
steatosis.
Obese humans with and without stea-
tosis presented with higher O2 flux rates
both in liver tissue and isolated mitochon-
dria compared to controls, in the context
of comparable peripheral insulin resis-
tance and normal hepatic insulin sensi-
tivity. This is in line with the elevated
hepatic mitochondrial activity observed
in obese mouse models (Buchner et al.,
2011). The greater respiratory capacity
in OBE NAFL and NAFL+ was not due
to differences in mitochondrial content.
In obese humans, Nair at al. found lower
hepatic ATP content using 31P-MRS
(Nair et al., 2003) but provided no infor-
mation on insulin resistance or presence
of NAFLD. Reduced hepatic ATP may
coexist with elevated respiration in the
setting of mitochondrial uncoupling.
Lower hepatic RCR of obese humans
with and without NAFL in the current
study provides evidence for decreased
coupling and suggests that elevated
respiration does not necessarily reflect
efficient ETC. Inefficient ETC may be pre-
sent in obese humans with NAFL, despite
an upregulation of mitochondrial path-
ways upstream of respiration such as
TCA cycle and b-oxidation (Sunny et al.,2011). In the present study, OBE NAFL and NAFL+ featured
similarly increased hepatic lipid peroxidation, likely due to
augmented respiration and impaired coupling. Hepatic ROS pro-
duction and oxidative DNA damage were not significantly
elevated, which can result from their intact anti-oxidant defense
capacity. Nevertheless, NAFL+ differed from NAFL by lower
hepatic expression of PGC-1a, NRF1, and TFAM, indicating–746, May 5, 2015 ª2015 Elsevier Inc. 743
impaired mitochondrial biogenesis, as confirmed by lower ETC
complex expression. These alterations may pave the way to
NAFLD progression.
OBE NASH featured lower respiration along with reduced
RCR. Mitochondrial uncoupling, already evident in OBE NAFL
and NAFL+, was aggravated in NASH, who had further elevated
hepatic LCR, reflecting increased proton leak across mitochon-
drial membrane. This may explain the higher H2O2 emission from
ETC, challenging the anti-oxidant defense capacity. Indeed,
NASH patients had reduced hepatic catalase activity in line
with the downregulated catalase expression reported in murine
NASH models (Gornicka et al., 2011). In turn, the increased he-
patic 8-OH-dG indicates hepatocellular oxidative damage in
agreement with previous reports, suggesting enhanced nuclear
expression of 8-OH-dG in hepatocytes of NASH patients (Seki
et al., 2002). Interestingly, hepatic CSA was higher, while ETC
complex expression tended to be lower in NASH. As a result,
the ratio of ETC complex expression to CSA was even lower in
NASH, indicating lower density of functional mitochondria, in
line with reports of abnormal mitochondrial morphology in livers
of NASH patients (Sanyal et al., 2001). The higher mitochondrial
mass in NASH does not necessarily require increased mitochon-
drial biogenesis but may alternatively result from reduced
degradation of damaged and dysfunctional mitochondria
(Wang et al., 2015).
OBE NASH also exhibited higher circulating triglycerides and
glucose, both of which may contribute to insulin resistance and
abnormal energy metabolism. Hepatic lipid overload may have
stimulated mitochondrial respiration, creating a pseudo-hypoxic
state with induction of deleterious oxidative modifications of
mitochondrial proteins (Mantena et al., 2009), promoting
impaired respiration. On the other hand, patients with T2DM
and hepatic insulin resistance exhibit both lower in vivo
measured hepatic ATP content (Szendroedi et al., 2009) and
flux through ATP synthase (Schmid et al., 2011), pointing to a
possible role of circulating glucose. In the present study, hepatic
insulin resistance in NASH coexisted with increased hepatic
JNK activity, a key regulator of NAFLD pathogenesis, which is
also upregulated in insulin-resistant mouse models (Singh
et al., 2009).
Only OBE NASH had markedly elevated circulating IL6 levels,
indicating that cytokine-mediated pathways do not uniformly
precede hepatic insulin resistance and NASH in humans. The
link between fatty acids,mitochondrial uncoupling, and systemic
inflammationmight be also relevant for cardiovascular NASH co-
morbidities (Freigang et al., 2013). Not only cytokines, but also
the hepatokine FGF21 was altered in OBE NAFL+ and even
more in NASH. Serum FGF21 correlated positively with hepatic
insulin resistance, supporting the contention that FGF21 may
serve as biomarker of increased hepatic lipid availability associ-
ated with hepatic insulin resistance (Chavez et al., 2009).
One might speculate that FGF21 could also reflect lower
hepatic respiration of NASH, in view of the data linking FGF21
to impaired muscle mitochondrial respiration (Suomalainen
et al., 2011).
This study benefits from simultaneous assessment of multiple
features of mitochondria in intensively phenotyped volunteers,
but its cross-sectional design does not allow conclusions on
causal relationships. Furthermore, although there is currently744 Cell Metabolism 21, 739–746, May 5, 2015 ª2015 Elsevier Inc.no gold standard for relatingmitochondrial function tomitochon-
drial content, the present study revealed similar results when ex-
pressing respiration rates either per protein or additionally by
CSA. Finally, although NASH patients with diabetes displayed
good metabolic control and comparable mitochondrial features
as other NASH patients, an effect of chronic moderate hypergly-
cemia on the observed mitochondrial abnormalities cannot be
excluded.
Taken together, we propose that increased lipid availability in
the liver of obese humans with and without steatosis stimulates
hepatic mitochondrial capacity and thereby serves to protect
against NAFLD progression. However, augmented respiration
may not be bioenergetically efficient due to leaking mitochondria
and thereby promote excessive hepatic oxidative stress, chal-
lenging hepatocellular anti-oxidant defense mechanisms. Once
these mechanisms fail, mitochondrial functionality decreases
and hepatic insulin resistance, NAFLD progression to NASH,
and systemic inflammation develop. In conclusion, these data
suggest an adaptation of hepatic mitochondria in obese humans
without NASH. This ‘‘hepatic mitochondrial flexibility’’ associ-
ated with early stages of human obesity could serve as future
target for the prevention and treatment of NAFLD.
EXPERIMENTAL PROCEDURES
Study Participants
We examined 53 volunteers: 41 obese undergoing bariatric surgery (OBE) and
12 healthy lean undergoing elective abdominal surgery such as cholecystec-
tomy or herniotomy (CON) (registered clinical trial, NCT01477957). Obese pa-
tients had stable body weight and were instructed not to follow a hypocaloric
diet before surgery to avoid confounding effects on hepaticmitochondria. OBE
were further classified into obese with steatosis (OBE NAFL+), without steato-
sis (OBE NAFL), and NASH (OBE NASH) based on liver histology. NASH was
defined by a composite outcome of steatosis, lobular inflammation, and hepa-
tocellular injury based on a validated histological NAFLD activity score ofR5
(Kleiner et al., 2005). All NASH patients displayed profound steatosis, 5 out of 7
lobular inflammation, 3 out of 7 signs of liver cell ballooning, and 6 out of 7 signs
of periportal fibrosis. NASH group included two males and one female with
well-controlled T2DM (mean HbA1c 7.5%), whose oral glucose-lowering
medication was replaced by insulin at least 1 week before study participation.
Before inclusion, all participants gavewritten informed consent to the protocol,
which was approved by the institutional review board (IRB) of Heinrich-Heine-
University Du¨sseldorf and conducted according to World’s Medical Associa-
tion Declaration of Helsinki.
Metabolic Characterization
Hyperinsulinemic-euglycemic clamps were combined with [6,6-2H2]glucose to
assess whole-body and hepatic insulin sensitivity (Szendroedi et al., 2007).
During the 180 min clamp (insulin 40 mU/m2 body surface area/min, Insuman
Rapid, Sanofi-Aventis Deutschland), blood glucose was kept at 90 mg/dl by
periodically adjusting the 20% glucose infusion (2% enriched with [6,6-2H2]
glucose).
Metabolic flexibility was assessed from standardized indirect calorimetry
with a computerized gas analyzer system (Vmax Encore 29n), as the change
in respiratory quotient from fasted to insulin-stimulated state. Whole-body in-
sulin-mediated glucose disposal (M value, Rd) and endogenous glucose pro-
duction (EGP) were calculated as described (Szendroedi et al., 2009). Hepatic
insulin sensitivity was assessed as insulin-stimulated EGP suppression (%).
Liver Biopsies
Biopsies were taken from the lower part of right liver lobe (200–700 mg tissue)
by surgeons 30 min after induction of anesthesia according to standardized
protocols. Approximately 50 mg was transferred into ice-cold preservation
medium (BIOPS solution) for HRR, 200 mg were placed into mitochondrial
isolation buffer (MiBO6) for mitochondrial isolation, 100 mg were fixed in 1%
formaldehyde for histological examination, and remaining tissue was rapidly
snap-frozen in liquid nitrogen and stored at 80C. Liver histology was per-
formed by an experienced hepatopathologist, according to standard tech-
niques using hematoxylin-eosin and Masson’s trichrome (Figure S2).
Mitochondrial Content and Function
Mitochondrial content was assessed from CSA and mtDNA (Benard et al.,
2006; Chiappini et al., 2006). Mitochondria were isolated by differential centri-
fugation (Frezza et al., 2007). O2 flux rates were measured with HRR in liver
tissue and isolated mitochondria (Oroboros oxygraphs, Innsbruck) upon
sequential exposure to mitochondrial substrates and titrating ADP concentra-
tions (Kuznetsov et al., 2002) and adjusted to individual CSA values to account
for mitochondrial content, in line with the majority of studies in this field (Man-
tena et al., 2009; Pe´rez-Carreras et al., 2003; Satapati et al., 2012) (for methods
see Supplemental Experimental Procedures). Isolated mitochondria were also
exposed to oligomycin in a separate protocol to assess leaking respiration
(Wikstrom et al., 2012). Respiratory control ratio (RCR) was defined as the ratio
of state 3 respiration to state o (oligomycin). Leak control ratio (LCR) was
defined as the ratio of state o to state u (after fccp).
Immunoblotting
ETC complex expression was quantified by SDS-PAGE in isolated mitochon-
dria (Mitosciences). 50 mg of mitochondrial protein were loaded per well and
b-actin (Cell Signaling Technology) was used to correct for loading control.
Data are expressed as ratio of signal of antibodies against ETC complexes
to antibodies against b-actin. Hepatic p-JNK Thr183/Tyr185 and CHOP
were quantified using specific antibodies (Cell Signaling Technology), and
GADPH expression was used for loading control.
Oxidative Stress
TBARS were measured in serum and liver (Jelenik et al., 2014). Amplex Red
(Molecular Probes) was used to measure hepatic H2O2 emission, reflecting
ROS production from complexes I and III after stimulation with succinate
and antimycin-A (Starkov, 2010). Catalase activity (Cayman Chemical Com-
pany) and 8-OH-dG (ELISA, Trevigen) weremeasured in hepatic tissue lysates.
Gene Expression Analyses
Relative quantification of hepatic mRNA expression of genes related to mito-
chondrial biogenesis (TFAM, PGC-1a, NRF-1) was assessed with real-time
PCR (QuantiTect Reverse Transcription Kit, QIAGEN) and the comparative
threshold cycle method (DDCt) with 18S ribosomal RNA as reference gene.
Statistical Analysis
Data are presented as means ± SEM. Comparisons were performed with one-
way ANOVA and correlations were analyzed with Spearman correlation. Differ-
ences were considered statistically significant at p < 0.05. All analyses were
performed with SPSS 19.0.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.04.004.
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